{"id":257,"date":"2020-06-04T05:23:37","date_gmt":"2020-06-04T05:23:37","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=257"},"modified":"2020-06-04T05:23:37","modified_gmt":"2020-06-04T05:23:37","slug":"03-june-2020-hydroxychloroquine-no-significant-benefit-in-postexposure-prophylaxis","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/03-june-2020-hydroxychloroquine-no-significant-benefit-in-postexposure-prophylaxis\/","title":{"rendered":"(03 June 2020) Hydroxychloroquine- no significant benefit in postexposure prophylaxis"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"m-article-header__title f-h18\"><span class=\"title_default\">A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19<\/span><\/p>\n<p class=\"\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2016638?query=featured_home<\/p>\n<p class=\"f-body\">This is a randomized, double-blind, placebo-controlled trial (<a class=\"ext-link\" href=\"http:\/\/clinicaltrials.gov\/show\/NCT04308668\" target=\"_blank\" rel=\"noopener noreferrer\">NCT04308668<span class=\"sr-only\">. opens in new tab<\/span><\/a>)across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis.&nbsp; Within 4 days after exposure, participants were randomly assigned to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. 821 asymptomatic participants were enrolled. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was \u22122.4 percentage points (95% confidence interval, \u22127.0 to 2.2; P=0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2016638?query=featured_home This is a randomized, double-blind, placebo-controlled trial (NCT04308668. opens in new tab)across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis.&nbsp; Within 4 days after exposure,&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/03-june-2020-hydroxychloroquine-no-significant-benefit-in-postexposure-prophylaxis\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(03 June 2020) Hydroxychloroquine- no significant benefit in postexposure prophylaxis&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,9],"tags":[59],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/257"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=257"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/257\/revisions"}],"predecessor-version":[{"id":258,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/257\/revisions\/258"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}